Loading institutional data...
Loading institutional data...
Held by 1,081 of 2,417 reporting institutions (100th percentile) — extremely crowded.
Data as of Q3 2026
Loading snapshot...
Loading financials...
Loading valuation...
Loading analysis...
Loading dividends & returns...
Loading capital allocation...
Loading debt & leverage...
Loading performance...
Loading peer comparison...
Loading insider activity...
Loading ownership map...
Loading crowding analysis...
Loading conviction analysis...
Loading buy/sell flow...
Loading ownership trends...
Loading top holders...
Loading top holders...
Total shares institutions bought (green) vs sold (red) each quarter across all holders.
Inferred from quarter-over-quarter change in each fund's 13F position (new stakes count as buys, exits as sells). Not tick-level trades.
Top 40 institutional holders — bubble size is position value, color is the move since last quarter. Hover any holder for detail.
Drag any bubble to rearrange · size = dollar value of the position
Ranked against 15 sector peers with collected financials. Valuation from latest close × latest fiscal-year fundamentals; 13F conviction as of 2026-09-30.
Percentile is “goodness” within the peer set (100 = best). For valuation and leverage that means cheaper / less-levered ranks higher.
| Company | Mkt cap ▼ | P/E | EV/EBITDA | P/S | Rev gr | Gross | Net | ROE | ROIC | Net D/EBITDA | 13F |
|---|---|---|---|---|---|---|---|---|---|---|---|
| LLY | $1.26T | 61.8× | — | 19.4× | 44.7% | 83.0% | 31.7% | 77.8% | 29.9% | — | 1,730 |
| JNJ | $657.7B | 24.8× | 20.9× | 7.0× | 6.0% | 67.9% | 28.5% | 32.9% | 20.7% | 0.9× | 1,839 |
| ABBV | $521.1B | 125.0× | 36.8× | 8.5× | 8.6% | 70.2% | 6.9% | -129% | 6.6% | 3.9× | 1,635 |
| MRK | $368.9B | 20.5× | — | 5.7× | 1.3% | 74.8% | 28.1% | 34.7% | 17.9% | — | 1,469 |
| ABT | $183.8B | 28.6× | 19.8× | 4.2× | 5.7% | 56.4% | 14.7% | 12.5% | 10.0% | 0.5× | 1,081 |
| PFE | $174.0B | 22.4× | — | 2.8× | -1.6% | 74.3% | 12.4% | 9.0% | 5.1% | — | 1,034 |
| VRTX | $141.7B | 36.5× | 31.2× | 11.8× | 8.9% | 86.2% | 32.9% | 21.2% | 21.2% | -1.2× | 568 |
| BMY | $127.7B | 18.1× | — | 2.6× | -0.2% | 71.1% | 14.6% | 38.2% | 11.1% | — | 904 |
| REGN | $95.5B | 22.4× | 22.9× | 6.7× | 1.0% | — | 31.4% | 14.4% | 13.6% | -0.3× | 408 |
| TEVA | $49.1B | 34.8× | 18.4× | 2.8× | 4.3% | 51.8% | 8.2% | 17.8% | 14.5% | -0.7× | 7 |
| ONC | $42.1B | — | 65.5× | 7.9× | 40.2% | 87.5% | 5.4% | 6.6% | 5.4% | -6.1× | 61 |
| ZTS | $32.9B | 13.2× | 10.4× | 3.5× | 2.3% | 71.8% | 28.2% | 78.3% | 21.5% | 1.7× | 388 |
| RPRX | $29.9B | 37.7× | 24.5× | 12.6× | 5.1% | — | 32.4% | 7.9% | 4.1% | 5.3× | 161 |
| UTHR | $25.7B | 21.5× | 15.3× | 8.1× | 10.6% | 87.9% | 41.9% | 18.8% | 18.8% | -1.0× | 202 |
| INSM | $24.7B | — | — | 40.7× | 66.7% | 79.7% | -211% | -173% | -99.8% | — | 154 |
| ALNY | $22.1B | 70.8× | 36.7× | 6.0× | 65.2% | 81.8% | 8.4% | 39.8% | 39.8% | -3.0× | 163 |
Peers = companies sharing ABT's sector (Pharmaceutical Preparations) with collected SEC financials. Multiples use the most recent end-of-day close and latest fiscal-year fundamentals (trailing, not forward). Missing cells mean the peer never reported that line item, has no collected price, or has a non-positive denominator. Not investment advice.
Solve the discounted cash flow backwards, then stress-test the assumptions.
Average free cash flow across the last 3 positive fiscal years (FY2023, FY2024, FY2025). Smooths the cycle. Stock compensation is NOT charged — it is added back inside operating cash flow.
To be worth $106.20 today, the market must believe free cash flow compounds 6.9%/yr for a decade (off $6.27B on the 3-yr avg basis).
On the basis ($5.61B) the requirement is 8.3%/yr. Shares issued to employees are added back in operating cash flow, so this basis treats them as free.
The market's 6.9% is more conservative than its 9-yr track record.
Default is 7.3% — this company's computed cost of capital (computed WACC), the same rate the Analysis tab discounts at.
2-stage DCF · 1.73B shares (market data) · net debt $4.41B
mean 21.2% · volatility σ 43% · implied rate exceeded in 6/9 yrs
Central path = implied 6.9%/yr growth; shaded band = ±1σ (43%) of this company's historical FCF volatility, widening with time. The wider the band, the less certain the growth.
Reverse DCF: rather than guessing a fair value, we solve for the growth the current price implies, then you stress-test the assumptions. Enterprise value of the FCF stream, less net debt, ÷ shares. Educational — not a recommendation.
What the company returns to shareholders — and whether it's covered by cash.
The dividend is comfortably covered — only 56% of free cash flow, leaving room to grow it and fund buybacks. Last year: $4.12B dividends + $893.0M buybacks = $5.01B returned on $7.39B FCF.
9 consecutive years of dividend increases · 10%/yr.
Yields use the latest fiscal-year dividends/buybacks over current market cap. Dividends and buybacks from the SEC cash-flow statement; payout coverage vs net income and free cash flow. Educational — not a recommendation.
How management deployed cash over 10 years — and what it earned on reinvestment.
A balanced mix of reinvestment and shareholder returns.
Modest payoff on reinvested capital. Current ROIC on all capital: 10%. Rough measure (includes maintenance capex).
Cash uses aggregated from the SEC cash-flow statement over 10 fiscal years. "Return on reinvestment" is a rough proxy — operating-income change ÷ cumulative CapEx + M&A — and includes maintenance capex. Educational — not a recommendation.
EOD close · as of 2026-10-30
How a revenue dollar becomes profit — FY2025
Dividends and buybacks are cash paid out, shown here against the same year's profit for scale — not funded from it.
Each value shows its share of revenue below it (common-size).
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $44.33B 100.0% | $41.95B 100.0% | $40.11B 100.0% | $43.65B 100.0% | $43.08B 100.0% | $34.61B 100.0% | $31.90B 100.0% | $30.58B 100.0% | $27.39B 100.0% | $20.85B 100.0% |
| Cost of Revenue | $19.32B 43.6% | $18.71B 44.6% | $17.98B 44.8% | $19.14B 43.9% | $18.54B 43.0% | $15.00B 43.4% | $13.23B 41.5% | $12.71B 41.6% | $12.41B 45.3% | $9.09B 43.6% |
| Cost of Products | — | — | — | — | — | — | — | — | $12.34B 45.0% | $9.02B 43.3% |
| Research & Development | $2.94B 6.6% | $2.84B 6.8% | $2.74B 6.8% | $2.89B 6.6% | $2.74B 6.4% | $2.42B 7.0% | $2.44B 7.6% | $2.30B 7.5% | $2.26B 8.3% | — |
| Selling, General & Admin | $12.33B 27.8% | $11.70B 27.9% | $10.95B 27.3% | $11.25B 25.8% | $11.32B 26.3% | $9.70B 28.0% | $9.77B 30.6% | $9.74B 31.9% | $9.18B 33.5% | $6.74B 32.3% |
| Total Operating Expenses | $36.27B 81.8% | $35.13B 83.7% | $33.63B 83.8% | $35.29B 80.8% | $34.65B 80.4% | $29.25B 84.5% | $27.37B 85.8% | $26.93B 88.1% | $25.83B 94.3% | $17.83B 85.5% |
| Operating Income | $8.05B 18.2% | $6.83B 16.3% | $6.48B 16.2% | $8.36B 19.2% | $8.43B 19.6% | $5.36B 15.5% | $4.53B 14.2% | $3.65B 11.9% | $1.56B 5.7% | $3.03B 14.5% |
| Interest Expense | $493.0M 1.1% | $559.0M 1.3% | $637.0M 1.6% | $558.0M 1.3% | $533.0M 1.2% | $546.0M 1.6% | $670.0M 2.1% | $826.0M 2.7% | $904.0M 3.3% | $431.0M 2.1% |
| Interest & Investment Income | $308.0M 0.7% | $344.0M 0.8% | $385.0M 1.0% | $183.0M 0.4% | $43.0M 0.1% | $46.0M 0.1% | $94.0M 0.3% | $105.0M 0.3% | $124.0M 0.5% | $99.0M 0.5% |
| Other Income (Expense), net | $548.0M 1.2% | $376.0M 0.9% | $479.0M 1.2% | $321.0M 0.7% | $277.0M 0.6% | $103.0M 0.3% | $191.0M 0.6% | $139.0M 0.5% | $1.41B 5.2% | -$786.0M -3.8% |
| Pretax Income | $8.47B 19.1% | $7.01B 16.7% | $6.66B 16.6% | $8.31B 19.0% | $8.21B 19.1% | $4.97B 14.4% | $4.08B 12.8% | $2.87B 9.4% | $2.23B 8.1% | $1.41B 6.8% |
| Income Tax Expense | $1.94B 4.4% | -$6.39B -15.2% | $941.0M 2.3% | $1.37B 3.1% | $1.14B 2.6% | $497.0M 1.4% | $390.0M 1.2% | $539.0M 1.8% | $1.88B 6.9% | $350.0M 1.7% |
| Net Income | $6.52B 14.7% | $13.40B 31.9% | $5.72B 14.3% | $6.93B 15.9% | $7.07B 16.4% | $4.50B 13.0% | $3.69B 11.6% | $2.37B 7.7% | $477.0M 1.7% | $1.40B 6.7% |
| Per Share | ||||||||||
| EPS (Basic) | $3.73 | $7.67 | $3.28 | $3.94 | $3.97 | $2.52 | $2.07 | $1.34 | $0.27 | $0.94 |
| EPS (Diluted) | $3.72 | $7.64 | $3.26 | $3.91 | $3.94 | $2.50 | $2.06 | $1.33 | $0.27 | $0.94 |
| Weighted Avg Shares (Basic) | 1.74B | 1.74B | 1.74B | 1.75B | 1.77B | 1.77B | 1.77B | 1.76B | 1.74B | 1.48B |
| Weighted Avg Shares (Diluted) | 1.75B | 1.75B | 1.75B | 1.76B | 1.79B | 1.79B | 1.78B | 1.77B | 1.75B | 1.48B |
Source: SEC EDGAR XBRL filings (annual, fiscal year). Quarterly flow items are derived from cumulative filings; balance-sheet figures are as-of each period end. Ratios and margins are computed, not reported.
How much the company owes, how it's trended, and how comfortably it's serviced.
Cash of $8.52B covers the $3.00B due within a year 2.8× over. Scheduled principal only (excludes interest & revolver draws). As of 2025-12-31 (10-K).
Green ≤ 1.5× · amber ≤ 3× · red > 3× (leverage relative to cash earnings).
Interest is easily covered by operating profit. Effective rate ~3.8% on $12.93B of debt.
Cash of $8.52B fully covers short-term debt of $3.03B.
Mostly long-term debt (balance-sheet current vs non-current split). See the maturity ladder above for the year-by-year repayment schedule.
Debt, cash, interest and equity from the SEC balance sheet & income statement. Effective rate = interest ÷ average debt. Maturity ladder from the SEC long-term-debt repayment schedule. Educational — not a recommendation.
Total return (dividends reinvested) vs the market, from quarter-end prices.
Above 0 = ahead of the S&P 500 since the window start; below 0 = behind. Rising means it's pulling ahead.
How far the stock fell below its prior peak. Deeper, longer drawdowns = a rougher ride to the same return.
Quarter-end, dividend-adjusted (total return). Beta & volatility from quarterly returns (annualized). Benchmark is the S&P 500 (SPY total return). Annual returns compound the quarters ending in each calendar year; the first and last years in a window may be partial. Past performance doesn't predict future results.
EOD close · as of 2026-10-30
Where each multiple sits in its own 14-yr range · 46th pct blended
Dot = today · shaded = middle 50% · line = median. Lower percentile = cheaper vs its own 14-yr history.
Is the profit real, and how strong is the balance sheet?
FY2025 · every deduction from revenue to net income
DuPont — the three levers
ROE 13% against ROIC 10% — 2% of the return on equity comes from leverage and buybacks rather than from the operating business.
What the company owes vs. what it holds
This shows debt/cash structure and net leverage. The year-by-year maturity schedule is on the Debt & Leverage tab.
Latest year: profit growth vs revenue growth
High operating leverage: profit moved 3.2× as fast as sales — great in an upturn, painful in a downturn.
Each line as % of revenue — the trend in color
| % of revenue | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Cost of Revenue | 41.6 | 41.5 | 43.4 | 43.0 | 43.9 | 44.8 | 44.6 | 43.6 |
| R&D | 7.5 | 7.6 | 7.0 | 6.4 | 6.6 | 6.8 | 6.8 | 6.6 |
| SG&A | 31.9 | 30.6 | 28.0 | 26.3 | 25.8 | 27.3 | 27.9 | 27.8 |
| Operating Income | 11.9 | 14.2 | 15.5 | 19.6 | 19.2 | 16.2 | 16.3 | 18.2 |
| Income Tax | 1.8 | 1.2 | 1.4 | 2.6 | 3.1 | 2.3 | -15.2 | 4.4 |
| Net Income | 7.7 | 11.6 | 13.0 | 16.4 | 15.9 | 14.3 | 31.9 | 14.7 |
Green = margin-favorable vs the row's own range · red = unfavorable.
The metrics that matter, over time
A 30-second read on ABT: price, valuation and headline fundamentals from SEC filings. The four questions at the top of the page are where the judgements live.
Earns 5.62pts above its cost of capital, positive in 5 of the last 5 years.
| Period | ROIC | Cost of capital | Spread |
|---|---|---|---|
| FY2019 | 9.9% | 7.3% (today's — no rate published for this year) | 2.6pts |
| FY2020 | 11.5% | 7.3% (today's — no rate published for this year) | 4.2pts |
| FY2021 | 18.3% | 5.4% | 12.8pts |
| FY2022 | 18.3% | 7.4% | 10.9pts |
| FY2023 | 13.4% | 7.9% | 5.5pts |
| FY2024 | 12.2% | 7.7% | 4.5pts |
| FY2025 | 13.7% | 6.6% | 7.2pts |
| Now | 10.0% | 7.3% | 2.7pts |
| Fiscal year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| FY2016 | 56.4% | 14.5% | 6.7% |
| FY2017 | 54.7% | 5.7% | 1.7% |
| FY2018 | 58.4% | 11.9% | 7.7% |
| FY2019 | 58.5% | 14.2% | 11.6% |
| FY2020 | 56.6% | 15.5% | 13.0% |
| FY2021 | 57.0% | 19.6% | 16.4% |
| FY2022 | 56.1% | 19.2% | 15.9% |
| FY2023 | 55.2% | 16.2% | 14.3% |
| FY2024 | 55.4% | 16.3% | 31.9% |
| FY2025 | 56.4% | 18.2% | 14.7% |
Leverage and buybacks account for 2 points of the 13% return on equity in FY2025. The business earns 10% on the capital it employs; the rest is balance sheet.
ROE is on average equity; ROIC is NOPAT over average invested capital (debt plus equity less excess cash). The gap is not a single adjustment.
$35.2B of goodwill — 57% of invested capital. The gap is what was paid above the fair value of what was bought; it is real capital shareholders provided, so neither bar is the whole answer. With goodwill over half the base, the ex-goodwill figure divides by a small remainder and moves sharply — read it as a direction, not a precise rate.
ROIC ex-goodwill is 29.97% against 12.97% reported — the return is earned on a capital base inflated by what was paid for acquisitions, not by the operating business alone.
Converts 0.97x of reported profit into cash — adequate, without much margin.
The cash conversion cycle has lengthened +26 days over 3 years to 108 — that many more days of the company's own cash funding the same volume of business.
Covers interest 11.4x even after a 30% EBITDA decline.
| EBITDA decline | Interest coverage |
|---|---|
| 0% | 16.33x |
| 5% | 15.52x |
| 10% | 14.70x |
| 15% | 13.88x |
| 20% | 13.07x |
| 25% | 12.25x |
| 30% | 11.43x |
| 35% | 10.62x |
| 40% | 9.80x |
| 45% | 8.98x |
| 50% | 8.17x |
| 55% | 7.35x |
| 60% | 6.53x |
Ladder as of 2025-12-31 (10-K); cash from the 2025-12-31 balance sheet; FCF from FY2025.
Balance sheet at 2025-12-31. Undrawn revolving credit is not shown: the tag is collected but not yet mapped through to the API.
The maturity schedule is not part of this verdict — its filing anchor is often older than the balance sheet it sits beside, so a wall inside 24 months may not be visible here.
At $106.20, free cash flow must compound 6.97%/yr for 10 years. It has done 8.64%/yr over 6 years.
| Fiscal year | FCF growth | Price requires |
|---|---|---|
| FY2020 | 27.3% | 7.0% |
| FY2021 | 51.1% | 7.0% |
| FY2022 | −9.8% | 7.0% |
| FY2023 | −35.2% | 7.0% |
| FY2024 | 25.5% | 7.0% |
| FY2025 | 16.4% | 7.0% |
The percentile ranks the FISCAL-YEAR point, because the distribution behind each strip is built from fiscal-year closes — ranking a TTM figure inside it would compare two different bases. TTM basis: TTM.
The implied rate has been matched or beaten in 4 of the last 6 years.
| Step | Amount | Running total |
|---|---|---|
| Net income | $6.52B | $6.52B |
| Share-based comp | $664M | $7.19B |
| Other non-cash & working capital | $2.38B | $9.57B |
| Operating cash flow | $9.57B | $9.57B |
| Capex | −$2.17B | $7.39B |
| Free cash flow | $7.39B | $7.39B |
| FCF after SBC | $6.73B | $6.73B |
| Fiscal year | Revenue growth | Receivables growth | Gap |
|---|---|---|---|
| FY2020 | 8.5% | 18.2% | 9.8 points |
| FY2021 | 24.5% | 1.1% | -23.3 points |
| FY2022 | 1.3% | -4.2% | -5.5 points |
| FY2023 | -8.1% | 5.6% | 13.7 points |
| FY2024 | 4.6% | 5.5% | 0.9 points |
| FY2025 | 5.7% | 14.5% | 8.8 points |
| Fiscal year | DSO | DIO | DPO | Cash conversion cycle |
|---|---|---|---|---|
| FY2019 | 62.1 days | 119.1 days | 89.7 days | 91.4 days |
| FY2020 | 67.6 days | 121.9 days | 96 days | 93.6 days |
| FY2021 | 55 days | 101.5 days | 86.8 days | 69.7 days |
| FY2022 | 52 days | 117.7 days | 87.8 days | 81.9 days |
| FY2023 | 59.7 days | 133.4 days | 87.2 days | 105.9 days |
| FY2024 | 60.3 days | 120.9 days | 81.9 days | 99.3 days |
| FY2025 | 65.3 days | 122.6 days | 80.1 days | 107.8 days |
| Fiscal year | Accruals / assets |
|---|---|
| FY2019 | -3.6 percent |
| FY2020 | -4.7 percent |
| FY2021 | -4.6 percent |
| FY2022 | -3.6 percent |
| FY2023 | -2.1 percent |
| FY2024 | 6.0 percent |
| FY2025 | -3.5 percent |
Below the line, the asset base is being consumed faster than it is replaced.
Depreciation here includes amortisation of acquired intangibles — goodwill written down over time, customer lists, acquired technology. Capex does not replace those and is not meant to, so an acquisitive or asset-light company sits below 1.0 permanently and correctly. The signal is cleanest for capital-intensive businesses, where the two measure the same physical base. For that reason this informs the earnings-quality verdict but never caps it.
SBC is added back inside operating cash flow, so reported free cash flow treats shares issued to employees as free. Percent of revenue says how expensive the payroll is; percent of operating cash flow says how much of the cash exists only because the charge was added back. The buyback offset is buybacks over SBC — below 1.0 the repurchase does not cover the shares issued.
Figures are the latest fiscal year (FY2025) from the company's own filings, not a trailing-twelve-month window — Q2 reads fiscal years throughout so the cash-conversion ratios and these share one basis. A blank is a line the filer did not report; it is never read as zero.
Last reported position per insider, carried forward. Steps can be a holding disclosed for the first time rather than a trade.
| Date | Insider | What it was | Shares | Price | Value |
|---|---|---|---|---|---|
| 2026-09-30 | Ahuja Nita Director | Grant | 318 | $98.83 | — |
| 2026-09-30 | Conroy Kevin T Director | Grant | 318 | $98.83 | — |
| 2026-09-30 | Gonzalez Patricia Paola Director | Grant | 333 | $98.83 | — |
| 2026-09-30 | Roman Michael F Director | Grant |
Every row is classified by what it MEANT, not by its SEC code. A code is not a meaning: code P (“purchase”) also covers dividend reinvestment and employee stock purchase plans, and code S (“sale”) also covers 10b5-1 plan sales scheduled months earlier and option exercises sold the same day.
Across 30 days of all filings, $5.08bn of insider selling contained $3.50bn of plan sales and $0.46bn of exercise-and-sell. Only 29% was discretionary. Reading an unclassified feed badly overstates how much insiders decided.
Buys and sales are counted separately and never netted. They are different decisions by different people; a company where one officer bought while another sold is not “neutral”.
The holding line carries each insider's last reported position forward, so it shows the total held rather than a sawtooth of whoever traded that day. It covers only insiders who filed in the window.
“Filed late” counts calendar days past the two-business-day deadline with five days' grace, so a Thursday or Friday trade crossing a weekend is never flagged. It describes the company's filing discipline, not the trade.
Insider activity is descriptive. Nothing here is investment advice.
| 381 |
| $98.83 |
| — |
| 2026-09-30 | Stratton John G Director | Grant | 397 | $98.83 | — |
| 2026-09-23 | Conroy Kevin T Director | Tax withholding | 52,507 | $103.99 | $5.5m |
| 2026-09-02 | 2 co-filers VICE PRESIDENT AND CONTROLLER | Open-market sale | 27 | $109.54 | $3k |
| 2026-09-01 | Boudreau Philip P EVP AND CFO | Tax withholding | 388 | $110.36 | $43k |
| 2026-09-01 | 2 co-filers VICE PRESIDENT AND CONTROLLER | Tax withholding | 52 | $110.36 | $6k |
| 2026-08-25 | 6 co-filers CHAIRMAN AND CEO | Option exercise | 151,869 | $44.40 | $6.7m |
| 2026-08-25 | 6 co-filers CHAIRMAN AND CEO | Option exercise | 246,963 | $59.94 | $14.8m |
| 2026-08-25 | 6 co-filers CHAIRMAN AND CEO | Exercise & sell | 218,535 | $115.57 | $25.3m |
| 2026-08-25 | 6 co-filers CHAIRMAN AND CEO | Exercise & sell | 180,297 | $116.19 | $20.9m |
| 2026-08-25 | 6 co-filers CHAIRMAN AND CEO | Option exercise | 151,869 | $0.00 | — |
| 2026-08-25 | 6 co-filers CHAIRMAN AND CEO | Option exercise | 246,963 | $0.00 | — |
| 2026-08-12 | 2 co-filers EXECUTIVE VICE PRESIDENT | Otherindirect | 12 | $107.99 | $1k |
| 2026-08-11 | 2 co-filers EXECUTIVE VICE PRESIDENT | Open-market sale | 5,850 | $109.83 | $643k |
| 2026-06-30 | Ahuja Nita Director | Grant | 347 | $90.74 | — |
| 2026-06-30 | Gonzalez Patricia Paola Director | Grant | 363 | $90.74 | — |
| 2026-06-30 | Morrone Louis H. EXECUTIVE VICE PRESIDENT | Tax withholding | 269 | $92.71 | $25k |
| 2026-06-30 | Roman Michael F Director | Grant | 416 | $90.74 | — |
| 2026-06-30 | Stratton John G Director | Grant | 432 | $90.74 | — |
| 2026-06-30 | Conroy Kevin T Director | Grant | 231 | $90.74 | — |
| 2026-06-27 | Cushman Elizabeth C. EVP, GC AND SECRETARY | Tax withholding | 560 | $94.12 | $53k |
| 2026-05-07 | Stratton John G Director | Open-market buy37d late | 2,000 | $86.82 | $174k |
| 2026-04-28 | Moreland Mary K EXECUTIVE VICE PRESIDENT | Otherindirect | 5,314 | $94.41 | $502k |
| 2026-04-27 | 3 co-filers Group filing | Open-market buy | 10,000 | $92.65 | $927k |
| 2026-04-24 | Babineaux-Fontenot Claire Director | Grant | 2,286 | $0.00 | $0 |
| 2026-04-24 | Kumbier Michelle Director | Grant | 2,286 | $0.00 | $0 |
| 2026-04-24 | Roman Michael F Director | Grant | 2,286 | $0.00 | $0 |
| 2026-04-24 | 2 co-filers Group filing | Grant | 2,286 | $0.00 | $0 |
| 2026-04-24 | Blount Sally E. Director | Grant | 2,286 | $0.00 | $0 |
| 2026-04-24 | Ahuja Nita Director | Grant | 2,286 | $0.00 | $0 |
| 2026-04-24 | Gonzalez Patricia Paola Director | Grant | 2,286 | $0.00 | $0 |
| 2026-04-24 | Mcdew Darren W Director | Grant | 2,286 | $0.00 | $0 |
| 2026-04-24 | Stratton John G Director | Grant | 2,286 | $0.00 | $0 |
| 2026-04-24 | Conroy Kevin T Director | Grant | 2,286 | $0.00 | $0 |
| 2026-04-24 | 2 co-filers Group filing | Grant | 2,286 | $0.00 | $0 |
| 2026-04-24 | 3 co-filers Group filing | Grant | 2,286 | $0.00 | $0 |
| 2026-04-24 | 2 co-filers Group filing | Grant | 2,305 | $0.00 | — |